| 2014年上半年国内22城市（地区）样本医院用药分析 |
| |
| 引用本文： | 徐培红,;干荣富. 2014年上半年国内22城市（地区）样本医院用药分析[J]. 世界临床药物, 2014, 0(11): I0018-I0023 |
| |
| 作者姓名： | 徐培红, 干荣富 |
| |
| 作者单位： | [1]上海交通大学医学院附属瑞金医院药剂科,上海200025; [2]国药控股股份有限公司,上海200051 |
| |
| 摘 要： | 本文分析了国内22城市（地区）样本医院用药数据，发现，近三年样本医院购入药品总金额增幅继续保持在12％左右，整个医院市场趋于平稳；抗感染药物目前己进入常态化管理，已从负增长的困境中走出，该大类药物在样本医院中所占份额不容忽视；供应医院领先厂商中进口、合资企业较本土企业稍占优势，提示，二三级医院对药品的临床使用效果或药品的来源及质量相当重视。
|
| 关 键 词： | 医院用药 政策影响 领先品种 领先厂商 |
A comprehensive survey of medication in domestic 22 area sample hospitals in the first half of 2014 |
| |
| Affiliation: | XU Pei-hong 1, GAN Rong-fu(1. Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025 2. Sinopharm Group Co., Ltd., Shanghai 2000051, China) |
| |
| Abstract: | In this review, a comprehensive analysis is made based on the drug-use data of domestic 22 area sample hospitals. The conclusion shows that the gross amount of drug purchase in sample hospitals maintains a growth rate of about 12% in recent 3 years. The whole hospital drug-use market is stable. The anti-infective drug has been turned into a normal management and has come out from the negative growth dilemma. According to the sales of leading manufacturing companies in this market, Multinational corporations and joint venture enterprises take a little advantage compared with the local ones. It shows that the clinical efficacy and drug quality are very important issues for the drug sources in hospitals. |
| |
| Keywords: | hospital drug-use policy influence leading product leading company |
| 本文献已被 维普 等数据库收录！ |
|
